Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK + oral AD) versus oral AD plus nasal placebo (oral AD + PBO) among patients with treatment-resistant depression. Patients & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK + oral AD versus oral AD + PBO over 52 weeks from multiple US payer perspectives. Clinical end points and cost inputs were derived from clinical trials and the literature, respectively. Results: Under the base-case scenario, the cost-per-remitter for ESK + oral AD and oral AD + PBO were as follows: Commercial: US$85,808 versus US$100,198; Medicaid: US$76,236 versus US$96,067; Veteran’s Affairs: US$77,765 versus US$104,519; and Integrated Delivery Network: US$103,924 versus US$142,766. Conclusion: The findings suggest that ESK + oral AD is a cost-efficient alternative treatment for treatment-resistant depression compared with oral AD + PBO.
Lay abstract
The US FDA recently approved esketamine nasal spray plus an oral antidepressant (AD) as a new treatment for adults with treatment-resistant depression. We developed an Excel-based model to understand whether esketamine + oral AD treatment offers better value for the money spent, compared with treatment with oral AD alone. We find that the higher annual costs of esketamine + oral AD treatment are more than offset by the better clinical outcomes achieved with this treatment. Specifically, in a given year, more people treated with esketamine + oral AD versus oral AD alone achieved and remained in remission, and as a result, they incurred fewer other medical costs.
Supplementary Material
File (suppl_file.docx)
- Download
- 65.24 KB
References
Papers of special note have been highlighted as: • of interest
1.
The US Burden of Disease Collaborators. The State of US Health, 1990–2016: burden of diseases, injuries, and risk factors among US states. JAMA 319(14), 1444–1472 (2018).
2.
Mitchell PM, Al-Janabi H, Richardson J, Iezzi A, Coast J. The relative impacts of disease on health status and capability wellbeing: a multi-country study. PLoS ONE 10(12), e0143590 (2015).
3.
Salomon J, Vos T, Hogan D et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380(9859), 2129–2143 (2012).
4.
Amos T, Tandon N, Lefebvre P et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression. J. Clin. Psych. 79(2), 1–9 (2018).
• Exemplifies the considerable economic and societal burden imposed by treatment-resistant depression (TRD) in the real-world, above and beyond that of major depressive disorder.
5.
American Psychiatry Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd Edition. (2010). https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
6.
Rush J, Trivedi M, Wisniewski S et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am. J. Psych. 163(11), 1905–1917 (2006).
7.
Steiner AJ, Boulus N, Wright SM et al. Major depressive disorder in patients with doctoral degrees: patient-reported depressive symptom severity, functioning, and quality of life before and after initial treatment in the STAR*D study. J. Psychiatr. Pract. 23(5), 328–341 (2017).
8.
Gaynes BN, Asher G, Gartlehner G et al. Definition of treatment-resistant depression in the Medicare population (2018). www.ncbi.nlm.nih.gov/books/NBK526366/pdf/Bookshelf_NBK526366.pdf
9.
Mrazek D, Hornberger J, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr. Serv. 65(8), 977–987 (2014).
10.
Little A. Treatment-resistant depression. Am. Fam. Physician 80, 167–172 (2009).
11.
Pilon D, Szukis H, Joshi K et al. US Integrated Delivery Networks perspective on economic burden of patients with treatment-resistant depression: a retrospective matched-cohort Study. Pharmacoecon Open. 4(1), 119–131 (2020).
• Finds that despite guidelines recommending otherwise, in the real-world, oral antidepressants remain the mainstay treatment among people with TRD and that use of nonpharmacological treatments such as electroconvulsive therapy and repeated transcranial magnetic stimulation is extremely limited.
12.
Szukis H, Benson C, Huang A et al. Economic burden of illness among US veterans with treatment-resistant depression. Presented at: Psych Congress. FL, USA, 25–28 October 2018.
13.
Pilon D, Sheehan JJ, Szukis H et al. Medicaid spending burden among beneficiaries with treatment-resistant depression. J. Comp. Eff. Res. 8(6), 381–392 (2019).
14.
Chow W, Doane M, Sheehan J, Alphs L, Le H. Economic burden among patients with major depressive disorder: an analysis of health care resource use, work productivity, and direct and indirect costs by depression severity. Presented at: AMCP Nexus Meeting. FL, USA, 22–25 October 2018.
15.
Shrestha A, Roach M, Joshi K et al. Incremental health care burden of treatment-resistant depression among Commercial, Medicaid, and Medicare payers. Psychiatr. Serv. 71(6), 593–601 (2020).
16.
Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev. Pharmacoecon. Outcomes Res. 16(4), 455–463 (2016).
17.
Ivanova J, Birnbaum H, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr. Med. Res. Opin. 26(10), 2475–2484 (2010).
18.
Janssen. Full prescribing information for SPRAVATOTM. www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
19.
Popova V, Daly EJ, Trivedi M et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am. J. Psych. 176(6), 428–438 (2019).
20.
Daly EJ, Trivedi M, Janik A et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psych. 76(9), 893–903 (2019).
21.
Hernandez LG, Li S, Toro-Diaz H, Zhang Q, Sheehan J, Le H. Cost-effectiveness analysis of esketamine in treatment-resistant depression in the United States. Value Health 22(Suppl. 2), S228–S229 (2019).
22.
Le HH, Zhang Q, Sheehan JJ. Budget impact analysis of esketamine in treatment-resistant depression in the United States. Value Health. 22(Suppl. 2), S229–S230 (2019).
23.
Agboola F, Atlas S, Touchette DR, Fazioli K, Pearson SD. The effectiveness and value of esketamine for the management of treatment-resistant depression: a summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council. J. Manag. Care Spec. Pharm. 26(1), 16–20 (2020).
24.
Agency for Healthcare Research and Quality. Identifying, categorizing, and evaluating health care efficiency measures. AHRQ Publication No. 08-0030 (2008). www.ahrq.gov/research/findings/final-reports/efficiency/hcemch2.html
25.
Sussman M, Yu J, Kamat SA et al. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. J. Affect. Disord. 207, 54–62 (2017).
• Used an evaluation approach similar to ours and in the same therapeutic area of TRD.
26.
Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J. Manag. Care 13, S8–S18 (2007).
27.
Ektare VU, Lopez J, Martin SC, Patel DA, Rupnow MFT, Botteman MF. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. Am. J. Manag. Care 20(Suppl. 10), S204–S215 (2014).
28.
Cannon AJ, Bargiota A, Billings L et al. Evaluation of the short-term cost-effectiveness of IDegLira versus basal insulin and basal-bolus therapy in patients with type 2 diabetes based on attainment of clinically relevant treatment targets. J. Manag. Care Spec. Pharm. 26(2), 143–153 (2020).
29.
Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA. Number needed to treat and cost per remitter for biologic treatments of Crohn’s disease in Japan. J. Med. Econ. 23(1), 80–85 (2020).
• Used an evaluation approach similar to ours.
30.
Teeple A, Muser E. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis. J. Med. Econ. 22(12), 1268–1273 (2019).
31.
Afonso M, Ryan F, Pitcher A, Lew E. Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain. J. Med. Econ. 20(6), 633–639 (2017).
32.
Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol. Psych. 63(7), 699–704 (2008).
33.
Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psych. 66(10), 1289–1297 (2005).
34.
Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psych. 68(2), 224–236 (2007).
35.
Thase ME, Youakim JM, Skuban A. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a Phase III, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J. Clin. Psych. 76, 1224–1231 (2015).
36.
Thase ME, Youakim JM, Skuban A. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a Phase III, randomized, double-blind study. J. Clin. Psych. 76, 1232–1240 (2015).
37.
Blumberger DM, Mulsant BH, Fitzgerald PB et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J. Biol. Psych. 13(6), 423–435 (2012).
38.
Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br. J. Psych. 190, 287–292 (2007).
39.
Red Book Online [database online]. Truven Health Analytics, Inc, CO, USA. www.ibm.com/products/micromedex-red-book
40.
Medicaid Drug Rebate Program (2020). www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html
41.
Janssen. Data on File.
42.
Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD). CNS Drugs 31, 421–432 (2017).
43.
Ross E, Zivin K, Maixner D. Cost–effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the United States. JAMA Psych. 75(7), 713–722 (2018).
44.
Voigt J, Carpenter L, Leuchter A. Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients – a lifetime analysis. PLoS ONE 12, 10 (2017).
45.
United States Bureau of Labor Statistics. Consumer Price Index for Medical Care (2020). www.bls.gov/cpi/factsheets/medical-care.htm
46.
Kaiser Family Foundation. Distribution of the nonelderly with Medicaid by family work status. State Health Facts. (2017). www.kff.org/medicaid/state-indicator/distribution-by-employment-status-4/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D
Information & Authors
Information
Published In
Pages: 393 - 407
PubMed: 33565893
Copyright
© 2021 Janssen Scientific Affairs, LLC. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 9 December 2020
Accepted: 13 January 2021
Published online: 10 February 2021
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0276
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Sajan Gunarathna, Yongha Hwang, Jung-Seok Lee, Existing Evidence from Economic Evaluations of Antimicrobial Resistance—A Systematic Literature Review, Antibiotics, 10.3390/antibiotics14111072, 14, 11, (1072), (2025).
- Mary Lou Chatterton, Johana Kevin Perez, Thao Thai, Jan Faller, Colleen K. Loo, Nick Glozier, David Barton, Bernhard T. Baune, Natalie T. Mills, Paul B. Fitzgerald, Paul Glue, Shanthi Sarma, Dusan Hadzi-Pavlovic, Vanessa Dong, Donel Martin, Philip B. Mitchell, Michael Berk, Gregory Carter, Maree Hackett, Sean Hood, Andrew A. Somogyi, Anthony Rodgers, Cathrine Mihalopoulos, Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial – The KADS study, Journal of Affective Disorders, 10.1016/j.jad.2025.119502, 387, (119502), (2025).
- J. Antoni Ramos-Quiroga, Fernando Mora, Silvia Arostegui, Narcís Cardoner, Jon-Inaki Etxeandia-Pradera, Rocío Gómez-Juanes, Marcos Gómez-Revuelta, José Manuel Montes, Eduard Vieta, Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects, The European Journal of Psychiatry, 10.1016/j.ejpsy.2025.100313, 39, 3, (100313), (2025).
- Lucio N. Gordan, Arielle G. Bensimon, Fan Mu, Nina Kim, Bingcao Wu, Dee Lin, Agne Paner, Jessica Fowler, Alex Marshall, Suzy Van Sanden, Eric Ammann, Joe Goble, Xinke Zhang, Hoa H. Le, Elissa E. Min, Louis P. Garrison, Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States, Journal of Medical Economics, 10.1080/13696998.2025.2514909, 28, 1, (910-920), (2025).
- Kristin Clemens, Amanda Teeple, Benoit Rive, Noam Kirson, Urvi Desai, Jason Doran, Diab Eid, Alice Qu, Hannah Bowrey, Kruti Joshi, Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression, Journal of Comparative Effectiveness Research, 10.57264/cer-2024-0092, 14, 7, (2025).
- Masayuki Saruta, Isao Kawaguchi, Yuji Ogawa, Yuri Sanchez Gonzalez, Naoki Numajiri, Xiaohe Tang, Russell Miller, Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib, Journal of Medical Economics, 10.1080/13696998.2024.2333683, 27, 1, (566-574), (2024).
- Isaure Estrade, Anne-Cécile Petit, Vincent Sylvestre, Michel Danon, Sylvain Leroy, Rebecca Perrain, Fabien Vinckier, Lila Mekaoui, Raphaël Gaillard, Emmanuelle Advenier-Iakovlev, Rossella Letizia Mancusi, Daphnée Poupon, Pierre De Maricourt, Philip Gorwood, Early effects predict trajectories of response to esketamine in treatment-resistant depression, Journal of Affective Disorders, 10.1016/j.jad.2023.09.030, 342, (166-176), (2023).
- Laura A. Hannah, Cathy M. Walsh, Louise Jopling, Jesus Perez, Rudolf N. Cardinal, Rory A. Cameron, Economic evaluation of interventions for treatment-resistant depression: A systematic review, Frontiers in Psychiatry, 10.3389/fpsyt.2023.1056210, 14, (2023).
- Madeline Brendle, Reid Robison, Daniel C. Malone, Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates, Journal of Affective Disorders, 10.1016/j.jad.2022.09.083, 319, (388-396), (2022).
- Madeline Brendle, Sachin Ahuja, Maisa Della Valle, Claire Moore, Paul Thielking, Daniel C Malone, Reid Robison, Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study, Journal of Comparative Effectiveness Research, 10.2217/cer-2022-0149, 11, 18, (1323-1336), (2022).